Acute respiratory distress syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
Line 6: Line 6:


==Pathophysiology==
==Pathophysiology==
[[Image:ARDS.jpg|thumb|A pathohistological image of ARDS.]]
ARDS typically develops within 24 to 48 hours of the provoking illness or injury and is classically divided into three phases:<br>
* ARDS is characterized by a diffuse inflammation of lung parenchyma.
*'''Exudative phase (''within 24-48 hours'')''': Systemic inflammation results in increased alveolar capillary permeability and leads to the formation of hyaline membranes along alveolar walls, accumulation of proteinaceous exudate within the alveolar air spaces (''non-cardiogenic pulmonary edema''), and extravasation of inflammatory cells (predominantly [[neutrophils|neutrophils]] and [[macrophages|macrophages]]) into the lung parenchyma, leading to extensive alveolar damage and sometimes hemorrhage into alveoli
* The triggering insult to the parenchyma usually results in an initial release of [[cytokines]] and other inflammatory mediators, secreted by local [[epithelium|epithelial]] and [[endothelium|endothelial]] [[cell (biology)|cell]]s.
*'''Proliferative phase (''within 5-7 days'')''': Fibroblast proliferation, collagen deposition, and early fibrotic changes are observed within the pulmonary interstitium as alveolar exudate and hyaline membranes begin to be absorbed
* [[Neutrophils]] and some T-[[lymphocytes]] quickly migrate into the inflamed lung parynchema and contribute in the amplification of the phenomenon.
*'''Fibrotic phase (''within several weeks'')''': Most patients with ARDS will develop some degree of pulmonary fibrosis, of which at least one-quarter will go on to develop a restrictive ventilatory defect on pulmonary function tests<ref name="pmid23520315">{{cite journal| author=Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP| title=The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. | journal=Eur Respir J | year= 2014 | volume= 43 | issue= 1 | pages= 276-85 | pmid=23520315 | doi=10.1183/09031936.00196412 | pmc=4015132 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23520315  }} </ref>; the development and extent of pulmonary fibrosis in ARDS correlates with an increased mortality risk<ref name="pmid7813276">{{cite journal| author=Martin C, Papazian L, Payan MJ, Saux P, Gouin F| title=Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients. | journal=Chest | year= 1995 | volume= 107 | issue= 1 | pages= 196-200 | pmid=7813276 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7813276  }} </ref>
* Typical histological presentation involves diffuse [[Pulmonary alveolus|alveolar]] damage and [[hyaline]] membrane formation in alveolar walls.
* Although the triggering mechanisms are not completely understood, recent research has examined the role of inflammation and mechanical stress.


===Inflammation===
===Genetic Susceptibility===
* Inflammation alone, as in sepsis, causes:
The role of genetics in the development of ARDS is an ongoing area of research. While studies have demonstrated associations between certain genetic factors (including [[single-nucleotide polymorphisms|single-nucleotide polymorphisms]] and allelic variants of [[angiotensin-converting enzyme|angiotensin-converting enzyme]]<ref name="pmid16484896">{{cite journal| author=Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL, Yang PC| title=Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. | journal=Crit Care Med | year= 2006 | volume= 34 | issue= 4 | pages= 1001-6 | pmid=16484896 | doi=10.1097/01.CCM.0000206107.92476.39 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16484896  }} </ref><sup>,</sup><ref name="pmid23364437">{{cite journal| author=Cardinal-Fernández P, Ferruelo A, El-Assar M, Santiago C, Gómez-Gallego F, Martín-Pellicer A et al.| title=Genetic predisposition to acute respiratory distress syndrome in patients with severe sepsis. | journal=Shock | year= 2013 | volume= 39 | issue= 3 | pages= 255-60 | pmid=23364437 | doi=10.1097/SHK.0b013e3182866ff9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23364437  }} </ref>) and increased susceptibility to developing ARDS, the nature and implications of these relationships remain uncertain.<ref name="pmid23048207">{{cite journal| author=Tejera P, Meyer NJ, Chen F, Feng R, Zhao Y, O'Mahony DS et al.| title=Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. | journal=J Med Genet | year= 2012 | volume= 49 | issue= 11 | pages= 671-80 | pmid=23048207 | doi=10.1136/jmedgenet-2012-100972 | pmc=3654537 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23048207  }} </ref>
:* Endothelial dysfunction
 
:* Fluid extravasation from the [[capillary|capillaries]]
===Pathology===
:* Impaired drainage of fluid from the lungs
*On gross pathology, the lungs are firm, boggy, and dusky, and they typically weigh more than healthy lungs due to edema
* Dysfunction of type II pulmonary epithelial cells may also be present, with a concomitant reduction in surfactant production.
*On microscopic histopathological analysis, the lung parenchyma demonstrates [http://www.wikidoc.org/index.php/File:Hyaline_membranes_-_very_high_mag.jpg hyaline membranes] lining the alveolar air spaces, edema fluid within alveoli and the interstitium, shedding of type I pneumocytes and proliferation of type II pneumocytes, infiltration of polymorphonuclear and other inflammatory cells into the interstitial and alveolar compartments, thrombosis and obliteration of pulmonary capillaries, and occasionally hemorrhage into alveoli
* Elevated inspired oxygen concentration often becomes necessary at this stage, and they may facilitate a '[[respiratory burst]]' in immune cells.
:*Features specific to the underlying disease process (e.g., [[pneumonia|bacterial pneumonia]] or [[aspiration pneumonitis|aspiration pneumonitis]]) are often seen as well
* In a secondary phase, endothelial dysfunction causes cells and inflammatory exudate to enter the alveoli
:*As ARDS progresses, alveolar infiltrates are reabsorbed and the inflammatory milieu is replaced by increased collagen deposition and proliferating fibroblasts, culminating in interstitial fibrosis
* This [[pulmonary edema]] increases the thickness of the alveolo-capillary space, increasing the distance the [[oxygen]] must diffuse to reach [[blood]].
 
* This impairs gas exchange leading to hypoxia, increases the work of breathing, eventually induces [[fibrosis]] of the airspace.
[[File:Hyaline membranes - very high mag.jpg|thumb|Hyaline membranes - very high magnification]]
* Rdema and decreased surfactant production by type II pneumocytes may cause whole [[Pulmonary alveolus|alveoli]] to collapse, or to completely flood. This ''loss of aeration'' contributes further to the right-to-left [[shunt]] in ARDS.
* As the alveoli contain progressively less gas, more blood flows through them without being oxygenated resulting in massive intrapulmonary shunting.
* Collapsed alveoli (and small [[bronchi]]) do not allow gas exchange. It is not uncommon to see patients with a PaO<sub>2</sub> of 60 mmHg (8.0 kPa) despite mechanical ventilation with 100% inspired oxygen.
* The loss of aeration may follow different patterns according to the nature of the underlying disease, and other factors. In pneumonia-induced ARDS, for example, large, more commonly causes relatively compact areas of alveolar infiltrates.
* Usually distributed to the lower [[lobe]]s, in their posterior segments, and they roughly correspond to the initial infected area.
* In [[sepsis]] or trauma-induced ARDS, infiltrates are usually more patchy and diffuse. The posterior and basal segments are always more affected, but the distribution is even less homogeneous.
* Loss of aeration also causes important changes in lung mechanical properties. These alterations are fundamental in the process of inflammation amplification and progression to ARDS in mechanically ventilated patients.


==References==
==References==

Revision as of 05:00, 20 June 2016

Acute respiratory distress syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute respiratory distress syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic study of choice

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Mechanical Ventilation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute respiratory distress syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute respiratory distress syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute respiratory distress syndrome pathophysiology

CDC on Acute respiratory distress syndrome pathophysiology

Acute respiratory distress syndrome pathophysiology in the news

Blogs on Acute respiratory distress syndrome pathophysiology

Directions to Hospitals Treating Acute respiratory distress syndrome

Risk calculators and risk factors for Acute respiratory distress syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Acute respiratory distress syndrome primarily results from the diffuse inflammation of lung parenchyma. Loss of aeration can cause fundamental changes in inflammation amplification and progression.

Pathophysiology

ARDS typically develops within 24 to 48 hours of the provoking illness or injury and is classically divided into three phases:

  • Exudative phase (within 24-48 hours): Systemic inflammation results in increased alveolar capillary permeability and leads to the formation of hyaline membranes along alveolar walls, accumulation of proteinaceous exudate within the alveolar air spaces (non-cardiogenic pulmonary edema), and extravasation of inflammatory cells (predominantly neutrophils and macrophages) into the lung parenchyma, leading to extensive alveolar damage and sometimes hemorrhage into alveoli
  • Proliferative phase (within 5-7 days): Fibroblast proliferation, collagen deposition, and early fibrotic changes are observed within the pulmonary interstitium as alveolar exudate and hyaline membranes begin to be absorbed
  • Fibrotic phase (within several weeks): Most patients with ARDS will develop some degree of pulmonary fibrosis, of which at least one-quarter will go on to develop a restrictive ventilatory defect on pulmonary function tests[1]; the development and extent of pulmonary fibrosis in ARDS correlates with an increased mortality risk[2]

Genetic Susceptibility

The role of genetics in the development of ARDS is an ongoing area of research. While studies have demonstrated associations between certain genetic factors (including single-nucleotide polymorphisms and allelic variants of angiotensin-converting enzyme[3],[4]) and increased susceptibility to developing ARDS, the nature and implications of these relationships remain uncertain.[5]

Pathology

  • On gross pathology, the lungs are firm, boggy, and dusky, and they typically weigh more than healthy lungs due to edema
  • On microscopic histopathological analysis, the lung parenchyma demonstrates hyaline membranes lining the alveolar air spaces, edema fluid within alveoli and the interstitium, shedding of type I pneumocytes and proliferation of type II pneumocytes, infiltration of polymorphonuclear and other inflammatory cells into the interstitial and alveolar compartments, thrombosis and obliteration of pulmonary capillaries, and occasionally hemorrhage into alveoli
  • Features specific to the underlying disease process (e.g., bacterial pneumonia or aspiration pneumonitis) are often seen as well
  • As ARDS progresses, alveolar infiltrates are reabsorbed and the inflammatory milieu is replaced by increased collagen deposition and proliferating fibroblasts, culminating in interstitial fibrosis
Hyaline membranes - very high magnification

References

  1. Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP (2014). "The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance". Eur Respir J. 43 (1): 276–85. doi:10.1183/09031936.00196412. PMC 4015132. PMID 23520315.
  2. Martin C, Papazian L, Payan MJ, Saux P, Gouin F (1995). "Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients". Chest. 107 (1): 196–200. PMID 7813276.
  3. Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL, Yang PC (2006). "Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome". Crit Care Med. 34 (4): 1001–6. doi:10.1097/01.CCM.0000206107.92476.39. PMID 16484896.
  4. Cardinal-Fernández P, Ferruelo A, El-Assar M, Santiago C, Gómez-Gallego F, Martín-Pellicer A; et al. (2013). "Genetic predisposition to acute respiratory distress syndrome in patients with severe sepsis". Shock. 39 (3): 255–60. doi:10.1097/SHK.0b013e3182866ff9. PMID 23364437.
  5. Tejera P, Meyer NJ, Chen F, Feng R, Zhao Y, O'Mahony DS; et al. (2012). "Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin". J Med Genet. 49 (11): 671–80. doi:10.1136/jmedgenet-2012-100972. PMC 3654537. PMID 23048207.


Template:WikiDoc Sources